Video

Importance of Quality of Life Endpoints in Clinical Trials

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

QoL endpoints are becoming an integral part of modern clinical trial designs. As such, the importance of QoL in clinical trials cannot be understated, explains Di Maio. QoL data are a critical part of clinical oncology as they inform the value of a particular treatment, he says. In recent years, ASCO and the ESMO have assembled frameworks by which to assess a treatment’s utility. QoL is one such parameter that has been included in the framework, says Di Maio.

Additionally, both the FDA and the European Medicine’s Agency have emphasized the importance of including QoL data among clinical endpoints in trials. In addition to informing the value of treatment, QoL can help patients understand the risks and benefits of therapy, he concludes.

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS